Belimumab
Belimumab
Belimumab (pronounced as bel-i-MOO-mab) is a monoclonal antibody that is used as a medication for the treatment of systemic lupus erythematosus (SLE).
Etymology
The name "Belimumab" is derived from the Latin words "bellum" meaning war, and "imunis" meaning immune, signifying its role in targeting the immune system.
Usage
Belimumab is used to treat adults with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. It is a B-lymphocyte stimulator (BLyS)-specific inhibitor that influences the immune system.
Mechanism of Action
Belimumab works by binding to the soluble human B-lymphocyte stimulator (BLyS) protein and inhibits its biological activity. The binding of belimumab to BLyS inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.
Side Effects
Common side effects of belimumab include nausea, diarrhea, and fever. Serious side effects may include infections, depression, and severe allergic reactions.
Related Terms
External links
- Medical encyclopedia article on Belimumab
- Wikipedia's article - Belimumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski